Brain metastases in gastro-oesophageal adenocarcinoma: insights into the role of the human epidermal growth factor receptor 2 (HER2).

Détails

Ressource 1Télécharger: 26313663_BIB_917B8A7CB530.pdf (178.87 [Ko])
Etat: Public
Version: Final published version
ID Serval
serval:BIB_917B8A7CB530
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Brain metastases in gastro-oesophageal adenocarcinoma: insights into the role of the human epidermal growth factor receptor 2 (HER2).
Périodique
British Journal of Cancer
Auteur(s)
Feilchenfeldt J., Varga Z., Siano M., Grabsch H.I., Held U., Schuknecht B., Trip A., Hamaguchi T., Gut P., Balague O., Khanfir K., Diebold J., Jochum W., Shoji H., Kushima R., Wagner D., Shimada Y., Cats A., Knuth A., Moch H., Aebi S., Hofer S.
ISSN
1532-1827 (Electronic)
ISSN-L
0007-0920
Statut éditorial
Publié
Date de publication
2015
Peer-reviewed
Oui
Volume
113
Numéro
5
Pages
716-721
Langue
anglais
Résumé
BACKGROUND: Gastro-oesophageal adenocarcinomas rarely metastasize to the central nervous system (CNS). The role of the human epidermal growth factor receptor 2 (HER2) in patients with these cancers and CNS involvement is presently unknown.
PATIENTS AND METHODS: A multicentre registry was established to collect data from patients with gastro-oesophageal adenocarcinomas and CNS involvement both retrospectively and prospectively. Inclusion in the study required a predefined clinical data set, a central neuro-radiological or histopathological confirmation of metastatic CNS involvement and central assessment of HER2 by immunohistochemistry (IHC) and in situ hybridisation (ISH). In addition, expression of E-cadherin and DNA mismatch repair (MMR) proteins were assessed by IHC.
RESULTS: One hundred patients fulfilled the inclusion criteria. The population's median age was 59 years (interquartile range: 54-68), of which 85 (85%) were male. Twenty-five patients were of Asian and 75 of Caucasian origin. HER2 status was positive in 36% (95% CI: 26.6-46.2) of cases. Median time from initial diagnosis to the development of brain metastases (BMets) or leptomeningeal carcinomatosis (LC) was 9.9 months (95% CI: 8.5-15.0). Median overall survival from diagnosis was 16.9 months (95% CI: 14.0-20.7) and was not related to the HER2 status. E-cadherin loss was observed in 9% of cases and loss of expression in at least one DNA MMR proteins in 6%.
CONCLUSIONS: The proportion of a positive HER2 status in patients with gastro-oesophageal adenocarcinoma and CNS involvement was higher than expected. The impact of anti-HER2 therapies should be studied prospectively.
Pubmed
Web of science
Open Access
Oui
Création de la notice
05/10/2015 13:27
Dernière modification de la notice
27/09/2019 6:26
Données d'usage